Arexera Therapeutics, Inc. has highlighted the emerging preclinical profile of ATL-101, the company’s wholly owned investigational HTT-lowering therapy for Huntington’s disease (HD), and advancement of its global clinical development program following Investigational New Drug (IND) approval in China.
“The totality of preclinical data generated to date underscores our conviction in ATL-101 and its differentiated profile across key attributes – most notably, robust and durable HTT reduction throughout the brain including the striatum, the key brain region for HD,” said Joanne Kotz, CEO of Arexera.
“Taken together, we believe these findings support the best-in-class potential of ATL-101. With IND approval of our phase 1 study in China, we are now positioned to begin evaluating that profile in patients as part of our accelerated global clinical development strategy.”
ATL-101 is a novel, intrathecally administered, divalent siRNA (di-siRNA) designed to reduce expression of HTT, the disease-causing protein responsible for HD pathogenesis.
Across preclinical studies in NHPs, ATL-101 demonstrated broad CNS distribution, including penetration into disease-relevant deep brain structures in the striatum (e.g. caudate and putamen), as well as up to 80% HTT lowering in the striatum following a single administration, providing best-in-class HTT lowering in the striatum in NHPs reported to date.
The company said it also showed best-in-class durability, with max HTT lowering sustained through at least six months following a single administration. It also has a clean safety profile, including no drug-related clinical, safety biomarker, or histopathology observations at any dose tested in single and repeat dose GLP toxicology studies.
Arexera plans to present preclinical data characterizing ATL-101 at a medical meeting in 2027.
Following China’s National Medical Products Administration (NMPA) approval of Arexera’s IND application for ATL-101, the company expects to start a phase 1 clinical study in HD patients by year-end.
The study is being conducted in partnership with Tenacia Biopharmaceuticals, a China-based neurology-focused biotech with established clinical development capabilities, at Huashan Hospital affiliated with Fudan University.
The China phase 1 study is designed to evaluate safety and tolerability of ATL-101 in patients with HD. Secondary and exploratory objectives will include assessment of pharmacokinetics and pharmacodynamic biomarkers of target engagement and biological activity, including HTT lowering in the cerebrospinal fluid (CSF). Initial safety and HTT biomarker data are expected in mid-2027.
Results from the study are expected to establish clinical proof-of-mechanism and inform dose selection for a planned global phase 1/2 trial intended to establish clinical proof-of-concept. Arexera is advancing preparations for the planned global study in parallel with the execution of the China phase 1 study.
“People living with Huntington’s disease urgently need therapies capable of altering the course of their disease, and the preclinical profile of ATL-101 supports its potential to deliver meaningful clinical benefit,” said Pedro Gonzalez-Alegre, chief medical officer of Arexera.
“We look forward to initiating the China phase 1 study later this year and bringing this promising therapy to patients.”


